UPDATE: We wish to advise you that the Administrative Appeals Tribunal (AAT) has granted Aspen Australia’s application to stay the cancellation of products containing dextropropoxyphene (Di-Gesic and Doloxene) from the ARTG. This allows us the opportunity to have our appeal of the Therapeutic Goods Administration’s (TGA) decision to cancel the registrations heard by the AAT.
In a span of 11 years, Aspen Pharmacare Australia has become one of Australia's leading pharmaceutical companies, developing a reputation for reliable, regulated and affordable medicines. Aspen-marketed brands account for one out of seven prescriptions written in the country.
Aspen, South Africa's leading pharmaceutical company, has announced that all conditions precedent have been met for it to acquire the pharmaceutical business of Australian-based Sigma Pharmaceuticals Limited.
Aspen's high level of flexibility has shown demonstrable business outcomes in addition to the attraction/retention of diverse talent, including consistently meeting sales objectives and extremely high value customer relationships.